In the latest trading session,, 0.37 million Heron Therapeutics Inc (NASDAQ:HRTX) shares changed hands as the company’s beta touched 1.38. With the company’s most recent per share price at $1.67 changed hands at -$0.1 or -5.65% at last look, the market valuation stands at $254.39M. HRTX’s current price is a discount, trading about -135.33% off its 52-week high of $3.93. The share price had its 52-week low at $1.04, which suggests the last value was 37.72% up since then. When we look at Heron Therapeutics Inc’s average trading volume, we note the 10-day average is 1.16 million shares, with the 3-month average coming to 1.72 million.
Analysts gave the Heron Therapeutics Inc (HRTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HRTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Heron Therapeutics Inc’s EPS for the current quarter is expected to be -0.01.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX was in red as seen in intraday trades today. With action -25.11%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 9.15%, with the 5-day performance at -25.11% in the red. However, in the 30-day time frame, Heron Therapeutics Inc (NASDAQ:HRTX) is -27.07% down. Looking at the short shares, we see there were 32.07 million shares sold at short interest cover period of 12.22 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 76.14% from its recent market value. According to analyst projections, HRTX’s forecast low is 5 with 9 as the target high. To hit the forecast high, the stock’s price needs a -438.92% plunge from its current level, while the stock would need to soar -199.4% for it to hit the projected low.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Year-over-year growth is forecast to reach 9.62% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 37.08M. 3 analysts are of the opinion that Heron Therapeutics Inc’s revenue for the current quarter will be 38.85M. The company’s revenue for the corresponding quarters a year ago was 34.67M and 36.02M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 6.96%. The estimates for the next quarter sales put growth at 7.84%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.68%. The 2025 estimates are for Heron Therapeutics Inc earnings to increase by 50.00%.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.74% of Heron Therapeutics Inc shares while 76.02% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.58%. There are 76.02% institutions holding the Heron Therapeutics Inc stock share, with RUBRIC CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 17.5395% of the shares, roughly 26.71 million HRTX shares worth $93.5 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 4.68 shares estimated at $7.73 million under it, the former controlled 3.07% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.99% of the shares, roughly 3.03 shares worth around $5.0 million.
